Burrill: Biopharma no longer a shelter in the storm

Once upon a time, says biotech handicapper and investor G. Steven Burrill, biopharma stocks offered shelter during a market storm. Now, they're getting doused along with everybody else. "At one time, in periods of economic uncertainty, investors would move into the relative safety of biotech and pharma," said the high-profile Burrill, CEO of Burrill & Company. "However, this is no longer the case and for the foreseeable future biotech's fortunes will be linked with the performance of the...

Live From BIO: Burrill: Focus on patients, not molecules

The biopharma industry needs to focus less on molecules and more on patients. That was one of the key messages in Steven Burrill's annual state of the industry report presented at BIO earlier this week. The billionaire venture capitalist touched on many points previous panels have discussed. The economic crisis of 2009, healthcare reform and the ever-rising cost of healthcare have a created an environment in which the industry not only should change, but must change to meet the needs...